Grassley seeking FDA reform over Ketek issues

Share this article:

Senator Chuck Grassley (R-IA) has asked the HHS Inspector General to investigate the FDA's troubled approval of the Sanofi-Aventis antibiotic Ketek based exclusively on allegedly “unreliable” foreign safety data.

In a letter to FDA commissioner Andrew von Eschenbach Grassley recommended changes at the agency to ensure that it doesn't happen again.

“It is troubling, if FDA is approving new drugs based primarily on questionable data in order to incentivize companies to develop new antibiotics, especially when the drugs are for conditions that may not even require antibiotic treatment,” he wrote.

Grassley's 22-page letter alleged that FDA knowingly approved Ketek in 2004 exclusively on foreign safety data, an “unprecedented” occurrence, that were called unreliable at the time by FDA reviewers.

The FDA never fully followed up on its own recommendations against Ketek's approval, Grassley alleged, hinting that the sponsor knew of the trial data deficiencies but submitted them anyway. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...